Perrigo Co (Perrigo Co) Risk Assessment

View and export this data going back to 1991. Start your Free Trial

What is Perrigo Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Perrigo Co is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Perrigo Co's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Perrigo Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Perrigo Co's Risk Assessment falls into.

Perrigo Co (NYSE:PRGO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Perrigo Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Perrigo Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Perrigo Co (Perrigo Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perrigo Co PLC (NYSE:PRGO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

PIG:Germany

Address

The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74

Website

https://www.perrigo.com

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Executives

Robert Willis	officer: Acting CHRO	C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Alison Ives	officer: EVP & Chief Scientific Officer	C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Eduardo Guarita Bezerra	officer: EVP & Chief Financial Officer	C/O FRESH DEL MONTE PRODUCE INC., PO BOX 149222, CORAL GABLES FL 33134
Patrick Lockwood-taylor	director, officer: CEO	C/O PERRIGO COMPANY PLC, 430 MONROE AVE NW, GRAND RAPIDS MI 49503
Julia M Brown	director	C/O ABLE BRANDS CO., 30 HUDSON YARDS, NEW YORK NY 10001
Triona Schmelter	officer: EVP & President CSCA	2021 SPRING ROAD, SUITE 600, OAK BROOK IL 60523
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Svend Andersen	director	C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Murray S Kessler	director, officer: CEO	714 GREEN VALLEY ROAD, GREENSBORO NC 27408
Thomas Farrington	officer: Senior VP and CIO	4012 W. CANTERBURY CT., NEQUON WI 53092
Dillard James E Iii	officer: EVP, Chief Scientific Officer	6601 WEST BROAD STREET, RICHMOND VA 23230
Ronald Craig Janish	officer: EVP, Global Op. & Supply Chain	PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Grainne Quinn	officer: EVP, Chief Medical Officer	PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Albert Manzone	director	C/O MERISANT, AVENUE JEAN-JACQUES ROUSSEAU 7, NEUCHATEL V8 CH-2000
Kyle Hanson	officer: EVP & General Counsel